About Our Company
Peptimmune is a clinical stage biotechnology company developing peptide and peptide-copolymer therapeutics for the treatment of CNS and Autoimmune disorders. These therapies target MHC Class II molecules and modulating immune responses. Founded in 2002 and located in Cambridge, MA USA, the Company is led by an experienced management team and exploits its proprietary DEEP™ Technology to design peptides and peptide mixtures.
Meet Our Team
Ed Mascioli, MD
Vice President, Clinical Affairs
Prior to Peptimmune, he was at MPM Capital, a leading healthcare venture capital firm. While at MPM, he served on the boards of Arriva Pharmaceuticals, CGI Pharmaceuticals, Elixir Pharmaceuticals, Mindset, Oxagen, Peptimmune…
